Fig. 1. Concurrent immunostaining demonstrates the percentage of cells with colocalisation of NSD2 and EZH2 significantly increases in castrate-resistant prostate cancer (CRPC) compared to hormone-sensitive disease.

Immunochemistry was quantitated using VECTRA™ and INFORM software using a hormone response tissue microarray (hrTMA) (n = 36) with hormone-sensitive patients (n = 18) and hormone-resistant patients (n = 18). a NSD2 and EZH2 association between core expression in tumour tissue. b Image of VECTRA immunostaining combinations for NSD2 and EZH2 in individual epithelial cells demonstrating overlapping staining. c Mean H-score of NSD2, d mean H-score of EZH2, e percentage of individual epithelial cells positive for both NSD2 and EZH2 signals compared between hormone-sensitive and hormone-resistant PC. f Percentage of individual epithelial cells negative for both NSD2 and EZH2 signals within each core. (p < 0.05 indicated by *, <0.01 indicated by ** and <0.001 indicated by ***).